(Use Google Chrome or Mozilla Firefox to secure your place)

16 October 2019 | Online | Free-to-attend

Simplifying Global Complexity:
The Role of AI from Licensing to Regulatory Compliance

The use of artificial intelligence (AI) across the pharmaceutical value chain was once theory. But it is quickly becoming the new reality for the industry.  
Across the drug development process, AI is being used to uncover hidden insights, manage complex data, drive efficiencies and reduce growing costs. While we are hearing an increasing number of use cases across the R&D and clinical space, we’ve yet to hear comprehensive insight into how other core functions can benefit from this innovative technology.

In this one day event, we’ll bring together industry experts to show you exactly how to benefit from regulatory and competitive intelligence.

For both the regulatory function and business development and licensing, the volume of information to monitor is increasing. This is a problem as accurate and timely decisions are becoming even more critical for success. Across three sessions, we’ll offer up a deep dive into how AI can tackle your core challenges and drive your regulatory and business development strategy forward.

Sign up now to attend the complimentary event live!

SESSION 1 :
Using AI and Competitive Intelligence for portfolio prioritization and evaluating external assets 

2pm-2:45pm [BST] 

SPEAKER: Ketan Patel, Product Director - Portfolio, Licensing and Clinical, Clarivate Analytics

In this session, we will explore how AI can help you and your organization to:
  • Utilize historical data to create models to identify paths and time to approval for drug development programs
  • Use statistical modelling and data-driven evidence to value an internal portfolio, evaluate external assets and make comparisons
  • Create forecast predictions for each aspect of drug development projects
  • Speed up business development decision making using statistical models
  • Understand the importance of early communication with Regulatory and other key functions to increase drug and program success

SESSION 2 :
Winning in global regulatory with AI: Advancing compliance, increasing approval rates and simplifying market expansion

3pm-3:45pm [BST]

SPEAKERS: Darin Oppenheimer, Executive Director for Regulatory Devices & Digital Health Solutions at Merck and Rick Finch, Global Head of Life Sciences Consulting Services, Clarivate Analytics

In this session, we will explore how AI can help you and your organization to:
  • Identify and overcome potential obstacles early on to remove barriers to success
  • Use regulatory intelligence to inform regulatory strategy, affairs and operations
  • Uncover hidden opportunities to improve performance
  • Understand and action key industry and regulatory trends
  • Increase collaboration and communication with Business Development & Licensing and other key functions to increase drug and program success

SESSION 3 :
The new drug life cycle: how AI and cross functional collaboration will revolutionize the process

4pm-4:45pm [BST]

SPEAKERS: Rick Finch, Clarivate Analytics, Darin Oppenheimer, Merck and Ketan Patel, Clarivate Analytics

In this session, we bring together a panel of speakers to answer your burning questions about AI and how to drive greater collaboration across functions. 

We'll recap the practical takeaways from the first two sessions and then have an in-depth discussion on some of the most pressing issues, queries and concerns about effective AI strategy across the drug life-cycle. 

You will be able to join the conversation by sharing your questions and comments to ensure you gain actionable insights to successfully power your strategy forward.

Our Expert Speakers

Rick Finch

Rick Finch

Global Head of Life Sciences Consulting Services

Clarivate Analytics

Darin Oppenheimer

Darin Oppenheimer

Executive Director, Regulatory Devices & Digital Health Solutions

Merck

Ketan Patel

Ketan Patel

Product Director - Portfolio, Licensing and Clinical

Clarivate Analytics